Stocks Health care IONS
NASDAQ · Health careIonis Pharmaceuticals Inc (IONS)
Ionis Pharmaceuticals Inc brought in $960.1M of revenue over the twelve months to September 30, 2026, down 0.7% from a year earlier. It posted a net loss of $546.5M. In fiscal 2025 capital spending exceeded operating cash flow by $320M. At September 30, 2026 it held $296.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Ionis Pharmaceuticals Inc
- Net worth
- Ionis Pharmaceuticals Inc has a market value (market cap) of $4.7B at the latest share price, and shareholders' equity of $393.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $943.7M (+33.8% year on year), with a net loss of $381.4M. Over the 12 months to September 30, 2026: revenue $960.1M, net loss $546.5M.
- Cash flow
- In fiscal 2025 operations used $268.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Ionis Pharmaceuticals Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Ionis Pharmaceuticals Inc does
Ionis Pharmaceuticals Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker IONS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $943.7M | -$381.4M | -$2.38 | -$320M |
| 2024 | $705.1M | -$453.9M | -$3.04 | -$546.2M |
| 2023 | $787.6M | -$366.3M | -$2.56 | -$331.3M |
| 2022 | $587.4M | -$269.7M | -$1.90 | -$290.1M |
| 2021 | $810.5M | -$28.6M | -$0.20 | $18.8M |
| 2020 | $729.3M | -$444.3M | -$3.18 | $772K |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where IONS ranks in Health care
Latest SEC filings
What Ionis Pharmaceuticals Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 55% to $242.7M versus the same quarter last year; diluted EPS -$0.66 versus -$0.80.
- November 9, 2026
- October 23, 2026
- October 21, 2026
- September 23, 2026
- September 4, 2026
- September 4, 2026
- July 31, 2026
- July 29, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 41% to $267.9M versus the same quarter last year; diluted EPS -$0.69 versus $0.70.
- July 29, 2026
Insider trades
What the people running Ionis Pharmaceuticals Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $61.4K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 16, 2026 | Swayze EricEVP Research | Soldindirect | 53 | $2.3K |
| October 16, 2026 | Devers Shannon L.EVP, Chief Human Resources Ofc | Sold | 1,357 | $59.1K |
| October 15, 2026 | Swayze EricEVP Research | Exercised optionsindirect | 125 | - |
| October 15, 2026 | Devers Shannon L.EVP, Chief Human Resources Ofc | Exercised options | 2,820 | - |
| August 31, 2026 | Birchler BrianEVP, Corp and Development Ops | Other change | 58 | $3K |
| August 31, 2026 | Monia Brett PChief Executive Officer, Director | Other change | 98 | $5K |
| August 31, 2026 | O'Neil Patrick R.EVP CLO & General Counsel | Other change | 63 | $3.2K |
| August 31, 2026 | Bennett C FrankEVP, Chief Scientific Officer | Other change | 110 | $5.6K |
Who owns IONS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Capital World Investors13G, passive | 12.8% | May 14, 2026 |
| Vanguard Capital Management13G, passive | 5.05% | April 30, 2026 |
| BB Biotech AG13G, passive with 1 related filers | 5% | November 14, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 513 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 24,631,956 | +75,319 |
| Capital World Investors | 21,669,226 | +482,857 |
| BlackRock, Inc. | 10,704,660 | +262,184 |
| Vanguard Portfolio Management LLC | 7,859,529 | +50,627 |
| Wellington Management Group Llp | 7,651,415 | +1,259,599 |
| Vanguard Capital Management LLC | 7,211,497 | +93,167 |
| Two Sigma Investments, LP | 6,252,342 | +394,713 |
| Royal Bank of Canada | 6,182,479 | +2,380,664 |
| State Street Corp | 4,334,848 | +339,284 |
| Geode Capital Management, LLC | 3,584,024 | -400,308 |
| Jpmorgan Chase & Co | 2,671,717 | +308,150 |
| Artisan Partners Limited Partnership | 2,640,024 | +581,716 |
| Tweedy, Browne Co LLC | 2,280,311 | +4,686 |
| Deep Track Capital, LP | 2,200,000 | +250,000 |
| Goldman Sachs Group Inc | 2,109,945 | +410,098 |
| Baker Bros. Advisors LP | 2,047,727 | 0 |
| Deerfield Management Company, L.P. | 1,979,669 | 0 |
| American Century Companies Inc | 1,947,076 | +283,273 |
| Franklin Resources Inc | 1,623,377 | +48,354 |
| Charles Schwab Investment Management Inc | 1,605,054 | +21,788 |
Insiders
20 insiders reported holding 1,159,110 shares in total, about $32.7M at the last price.
| Holder | Shares |
|---|---|
| Monia Brett PChief Executive Officer, Director | 242,760 |
| Berthelsen Spencer RDirector | 161,233 |
| Birchler BrianEVP, Corp and Development Ops | 102,883 |
| Hougen Elizabeth LEVP, Finance & CFO | 82,660 |
| Schneider EugeneEVP, Chf Clinical Develop Ofcr | 77,114 |
| Bennett C FrankEVP, Chief Scientific Officer | 60,128 |
| O'Neil Patrick R.EVP CLO & General Counsel | 59,205 |
| Wender Joseph HDirector | 52,03536,035 held indirectly |
| Parshall B LynneDirector | 51,344 |
| Herman Joan EDirector | 51,306 |
Questions about IONS
What does Ionis Pharmaceuticals Inc do?
Ionis Pharmaceuticals Inc is a company in the Health care sector, listed on NASDAQ as IONS. Its shares trade on NASDAQ under the ticker IONS.
What is Ionis Pharmaceuticals Inc's net worth?
Ionis Pharmaceuticals Inc has a market value (market cap) of $4.7B at the latest share price, and shareholders' equity of $393.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Ionis Pharmaceuticals Inc profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $546.5M on revenue of $960.1M.
How much revenue does Ionis Pharmaceuticals Inc make?
Over the twelve months to September 30, 2026 Ionis Pharmaceuticals Inc reported revenue of $960.1M. That is 0.7% less than a year earlier.
When did Ionis Pharmaceuticals Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Ionis Pharmaceuticals Inc's next earnings report?
Ionis Pharmaceuticals Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare IONS with
Follow IONS
Get an email when Ionis Pharmaceuticals Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Ionis Pharmaceuticals Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.